Coremap (Burglinton VT) is a development stage medical device company with advanced diagnostic technology to enable curative treatment options and improve outcomes for patients with complex cardiac arrhythmias like Atrial Fibrillation.  CoreMap technologies will allow for patient-specific treatments, because when treating patients with AF, ‘one size does not fit all.’  The Company has completed more than two dozen pre-clinical studies and recently closed a $10.5 million Series A financing.  Participating in DRIVEN and receiving guidance from the team was crucial when CoreMap was starting its fundraising efforts.  The expertise and perspective of the team have been invaluable both during and since the program.